This edition of the Global Fund PSD Newsletter contains
November 4-8 | Geneva, Switzerland
The Private Sector Delegation (PSD) to the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its biannual meeting ahead of the Global Fund’s Board Meeting in early November. PSD members discussed important decisions facing the Board, including preparation for the 2014 launch of the Fund’s new grant-making model, revisions to policies on eligibility and approval of the Fund’s performance assessment framework. PSD members also attended a side session on “TB and the Private Sector.” Further, newly-appointed PSD Board Member Paul Schaper, Alternate Board Member Renuka Gadde and the Secretariat’s Private Sector Team made a joint presentation to Board stakeholders on private sector engagement strategies.
After the PSD meeting, Schaper and Gadde went on to represent the private sector at the Global Fund Board meeting. Representatives from the following companies participated in the PSD and/or Global Fund Board meetings: Abt Associates, ALAFA, Anglo American, BD, Eli Lilly, Merck, Mylan, Novartis, Sanofi, Standard Diagnostics and TropMed Pharma.
Read more about the decisions and discussions at the Board meeting here.
October 22-23 | Hosted by Merck | Washington, D.C.
On October 22-23, representatives from 11 PSD companies met for the 3rd Annual Retreat, which was graciously hosted by Advisory Group member Merck. Members outlined the PSD’s 2014 priorities, set expectations for the private sector’s role in the 4th Replenishment, presented the findings of the report, Beyond Cash: More than Money, that analyzes private sector contributions to the Global Fund and launched a review of PSD internal policies and guidelines. Participants committed to proactively contribute private sector expertise to Global Fund work at both Board and in-country levels. Representatives from AbbVie, Abt Associates, BD, Eli Lilly, Gilead, Merck, Mylan, Novartis, Sanofi, TropMed Pharma, Vale and Vestergaard were in attendance.
December 2-3 | Replenishment Pledging Conference |
With an ambitious replenishment target of $15 billion still to be met, the Global Fund announced that the United States will host the Fourth Voluntary Replenishment Pledging Conference on December 2-3. The U.S. is the largest single donor to the Fund and, according to Congressional restrictions, its contribution cannot represent more than 33 percent of the total replenishment. Indicating a commitment to contributing the maximum allowable amount, President Obama has requested congressional approval for a $1.65 billion contribution in the 2014 budget. (If this level is maintained over the ensuing two years, the U.S. would contribute the maximum allowable amount of $5 billion out of a $15 billion total replenishment over 2014-2016.) Pledges from other countries total $4.66 billion so far.
Announcements to Date: Country Pledges 2014-2016
France: US$1.40 billion
The Fund is taking a multipronged approach to meeting the replenishment target, seeking pledges from developed countries, emerging economies, implementing countries, high net-worth individuals and the private sector. Private donors have also committed to the replenishment, such as the Tahir Foundation (Indonesia), which has pledged $65 million. This contribution was matched by the Bill & Melinda Gates Foundation, for a total of $130 million. Read more about the Global Fund’s 4th Voluntary Replenishment.
Insights for the Business Community
GBCHealth’s recent edition of its Insights newsletter examined the role the PSD plays in supporting the Global Fund. PSD companies have not only developed corporate health initiatives that advance the Fund’s mission, but have also engaged with the Fund in many other areas, including: establishing country-level partnerships, engaging with Board leadership and adding the private sector’s voice to policy deliberations. Read the newsletter to hear from the PSD’s current and former leadership and learn more about the work of the PSD.
The year-long analysis of the private sector’s contributions to the Global Fund has culminated in the report Beyond Cash: More Than Money. The report sheds light on some of the unique ways in which the private sector has supported the Global Fund’s mission, such as financial contributions, discounts on services, grant support, research and development, health systems strengthening and supplying products.
Led by TropMed Pharma and Abt Associates and supported by GBCHealth, the project team analyzed published data sources, including annual reports, company websites, surveys and procurement reports to assign monetary value to corporate contributions. The team also surveyed companies and interviewed Global Fund staff to estimate the level of co-investment contributions made by companies, yielding a more complete picture of the private sector’s overall engagement with the Global Fund. Read the full report here.
François Desbrandes, Deputy Director for Access to Medicines at Sanofi, was appointed to the Regional Steering Committee (RSC) overseeing a $100 million Global Fund grant in the Mekong region (Cambodia, Laos, Myanmar, Thailand and Vietnam). The RSC, which will function similarly to a Country Coordinating Mechanism but on a regional level, comprises representatives from government, civil society, foundations, development agencies and the private sector. The grant will fund an initiative to address the emergence of resistance to the malaria drug artemisinin in the region. Desbrandes brings several years of experience working at Sanofi’s Access to Medicines initiative, strong regional knowledge and insight into key malaria issues including artemisinin resistance, and is a member of the Roll Back Malaria Harmonisation Working Group.
October 9-10 | Hanoi, Vietnam
The Global Fund hosted a two-day event in Hanoi, bringing together over 70 representatives from across the public and private sectors. The group discussed the potential long-term value generation and sustainability of investing in the health of Vietnam’s consumer and labor force.
Participants discussed with representatives from the Ministry of Health, Ministry of Planning and Infrastructure and the Country Coordinating Mechanism the many challenges and opportunities facing Vietnam, from economic and health issues to public-private partnerships.
During the event, several public-private partnership opportunities to scale-up Global Fund-supported HIV/AIDS and malaria programs at the provincial level emerged. Follow-up work with partners is planned, with the goal of bringing these opportunities into fruition over the coming months.
Fake medicines are a threat to public health. Because illicit manufacturers evade regulation and quality control and pass these drugs off as something they are not, their use can lead to drug resistance, illness, disability and even death. In partnership with PharmaSecure, the Global Fund has launched a project to address the proliferation of counterfeit drugs in the Mekong region (Cambodia, Laos, Myanmar, Thailand and Vietnam). The program allows patients and healthcare workers to verify the authenticity of drugs by SMS. Read more about the project here.
BAYER: Preventing Malaria with an Integrated Vector Control Model
Malaria remains one of the major causes of death and illness worldwide, and mosquito control is crucial to managing the disease. Equipped with global research and development capabilities and a unique vector control portfolio, Bayer has played a leading role in malaria prevention for over 60 years. Bayer supports an integrated or “360⁰” approach to malaria vector control. Read more.
For the world to meet the health-related Millennium Development Goals, progress must be made in Nigeria, the most populous nation in Africa. Nigeria has the world’s second highest number of people living with HIV and, together with the Democratic Republic of Congo, accounts for 40 percent of global malaria deaths. Nigeria is slated to receive up to $288 million in interim funding under the Global Fund’s new funding model, providing a crucial opportunity to address the country’s disease burden. Nigeria’s recent increase in economic prosperity has also cemented its place as an emerging economy and created a thriving private sector. This provides the perfect environment for developing the public-private partnerships envisioned in the Global Fund’s mission. Read more about the state of the three diseases in Nigeria and the role the private sector can play in combatting them.
Week of January 27
Quarterly PSD Teleconference
PSD Pre-Board Meetings
Global Fund’s 31st Board Meeting
Week of April 28
Quarterly PSD Teleconference
More News and Updates here.
GLOBAL FUND NEWS AND UPDATES
23 October 2013
23 October 2013
21 October 2013
17 October 2013
15 October 2013
02 October 2013
25 September 2013
23 September 2013
20 September 2013
18 September 2013
05 September 2013
20 August 2013
16 July 2013
Board Member: Paul Schaper, Executive Director, Global Public Policy, Merck & Co.
Advisory Group Members
GBCHealth is the Focal Point for the Private Sector Delegation to the Global Fund, working with the committed companies of the Advisory Group to steer Global Fund priorities and policies, while also ensuring that the Global Fund actively engages the business sector.
For more information on how your company or private sector organization can get involved, please contact PSD Focal Point, Whitney White at firstname.lastname@example.org. Learn more about the Private Sector Delegation.